F-1/A: Cuprina Holdings Files for Public Offering Amidst Financial Losses

Cuprina Holdings (Cayman) Limited has filed an F-1/A registration statement for a public offering of Class A Ordinary Shares, detailing ongoing net losses and significant operational expenses, while highlighting progress in product development and market expansion strategies.

Summary

• Cuprina Holdings (Cayman) Limited is conducting a public offering of 4,322,489 Class A Ordinary Shares, with an estimated price range of $1.00 to $1.50 per share.
• The company reported net losses of S$1,560,535 for 2024 and S$4,673,447 (US$3,633,248) for 2025.
• Revenue for 2024 was S$48,321, increasing slightly to S$49,894 (US$38,789) in 2025, primarily driven by MEDIFLY product sales.
• Significant increases in selling, general, and administrative expenses, particularly professional fees, contributed to the widened net loss in 2025.
• The company plans to use the net proceeds for business expansion, R&D, market growth, brand awareness, and working capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a cautiously negative filing due to significant net losses, a history of operating losses, and substantial professional fees incurred post-IPO, despite progress in regulatory approvals and pipeline development.

Positives

• Received FDA 510(k) clearance for MEDIFLY products, enabling market entry into the United States.
• MEDIFLY products received official product classification as a Medical Device-Drug combination product from the Saudi Food and Drug Authority (SFDA), a key step for MENA region expansion.
• Strategic expansion plans for the Middle East (GCC) and mainland China are in place for the second half of 2026.
• Secured exclusive licensing rights for a medical waste recycling technology in Singapore and Southeast Asia.
• Completed construction of an ISO 13485-certified IVF media production facility in Singapore.
• Continued customer loyalty in the chronic wound care business, with 70.6% of customers from 2024 repurchasing in 2025.
• The company has a robust pipeline of chronic wound care products, including hirudotherapy and bullfrog collagen-based products.
• The company regained compliance with Nasdaq minimum bid price requirements.

Negatives

• Reported net losses of S$1,560,535 for 2024 and S$4,673,447 (US$3,633,248) for 2025.
• Accumulated deficit reached S$9,234,500 (US$7,179,118) as of December 31, 2025.
• Selling, general, and administrative expenses increased significantly by 228.5% in 2025, largely due to a substantial rise in professional fees related to the IPO and ongoing compliance.
• Cost of revenues exceeded revenue in both 2024 and 2025, resulting in gross losses.
• The company is an early-stage company with a history of losses and expects to incur losses in the future, with no assurance of achieving or sustaining profitability.
• Net cash used in operating activities was S$1,235,981 in 2024 and significantly increased to S$9,133,948 (US$7,100,947) in 2025.
• The company relies heavily on a few major customers, with the top five accounting for 65.7% of revenue in 2025.
• The maggot-based chronic wound care products, which constitute the majority of revenue, lack patent protection.

Risks

• The company is an early-stage company with a history of losses and expects to continue incurring losses, with no guarantee of achieving or sustaining profitability.
• Future growth prospects rely on industry development and consumer demand; failure to achieve market acceptance or retain customers could materially affect the business.
• Revenue growth is difficult to predict, and shortfalls could harm operating results due to fixed expenses.
• The company may not be able to develop new products that are competitive or successful in a timely manner.
• Reliance on R&D partners for know-how could lead to significant costs and delays if partners fail to perform adequately.
• Security breaches and other disruptions could compromise sensitive information and expose the company to liability.
• The company may not be able to maintain its listing on the Nasdaq, which could limit investor liquidity and subject it to additional trading restrictions.
• The dual-class share structure may adversely affect the trading market for Class A Ordinary Shares, and concentrated control by principal shareholders could limit minority shareholder influence.

Future Outlook

The company expects to continue incurring losses for the foreseeable future and cannot assure profitability. Future growth depends on successful product development, market acceptance, and expansion into new geographic markets. The company intends to use proceeds from the offering for business expansion, R&D, market growth, brand awareness, and working capital.

Management Comments

• We believe what sets us apart from our competitors is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure.
• We believe that the following competitive strengths have contributed to our success to date and will continue to distinguish us from our competitors: Innovative product portfolio that differentiates us from our competitors.
• We intend to continue to grow our business and further strengthen our market position by pursuing the following strategies: Expand into new geographic markets through strategic partnerships.
• We believe that a significant part of our success is attributable to our ability to select, develop, motivate and retain our talented and professional workforce.

Industry Context

StockSavvy.ai notes that Cuprina operates in the growing chronic wound care and cosmeceutical markets, driven by an aging population and increasing prevalence of chronic diseases. The company's focus on bio-therapeutics and natural sources, like bullfrog collagen, positions it to leverage these trends, though competition and regulatory hurdles remain significant.

Comparison to Industry Standards

• The global chronic wound care market is projected to reach US$29.22 billion by 2034, with a CAGR of 7.5%, indicating substantial market opportunity.
• The U.S. chronic wound care market was valued at US$4.43 billion in 2023 and is projected to grow at a CAGR of 6.8% from 2024 to 2032.
• The Southeast Asia advanced wound care market was valued at US$221.3 million in 2022 and is anticipated to grow at a CAGR of 6.1% from 2023 to 2030.
• The global medical waste management market was valued at approximately USD 34.06 billion in 2023 and is projected to reach approximately USD 59.42 billion by 2030, growing at a CAGR of approximately 8%.
• The total Assisted Reproductive Technology (ART) market was valued at approximately USD 38.9 billion in 2025 and is expected to grow at a CAGR of approximately 7.6% to reach approximately USD 79.8 billion by 2035.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal or administrative proceedings that are likely to have a material adverse effect on its business, financial condition, cash flow, or results of operations.

Related Party Transactions

• Advances for working capital and share subscriptions between the company and its shareholders, directors, and affiliated entities.
• Amounts due from and to related parties are generally interest-free, unsecured, and due on demand.
• The company has entered into various agreements with related parties for R&D, joint ventures, and distribution.

Stakeholder Impact

• Shareholders will experience immediate dilution in net tangible book value per share.
• Potential for reduced shareholder protection due to reliance on Cayman Islands law and controlled company exemptions from Nasdaq governance rules.
• Employees are subject to standard employment laws and CPF contributions in Singapore.
• Customers may benefit from innovative wound care and cosmeceutical products, with potential for improved treatment outcomes.
• Creditors and lenders are exposed to the company's financial performance and liquidity.

Next Steps

• Complete the public offering of Class A Ordinary Shares.
• Use net proceeds for business expansion, R&D, market growth, brand awareness, and working capital.
• Continue development of pipeline products, including hirudotherapy and bullfrog collagen-based products.
• Expand sales and establish physical operations in the Middle East (GCC) and mainland China in the second half of 2026.
• Prepare and submit regulatory dossiers for IVF media products with HSA, aiming for commercial sales before Q4 2027.
• Apply for operating licenses in Singapore to deploy the medical waste recycling technology.
• Commence safety and efficacy clinical trials for bullfrog collagen sponge dressings by the end of 2026.

Key Dates

Recommendation

The company shows promising pipeline development and regulatory progress, particularly with FDA clearance for MEDIFLY. However, the significant net losses, increasing operational expenses (especially professional fees post-IPO), and reliance on a few major customers present considerable risks. The current financial performance and high burn rate suggest a 'hold' recommendation, pending evidence of improved profitability and successful market penetration of new products.

Keywords

wound care, medical devices, biotechnology, maggot debridement therapy, bullfrog collagen, cosmeceuticals, IPO, registration statement